In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs.
The following faculty have disclosed:
Jeffrey Weber, MD, PhD, chair for this educational event, has received research funding from BMS, Merck, Incyte, Moderna, Regeneron, and Pfizer; has an ownership interest in Biond, Evaxion, OncoC4, and InstilBio; receives royalties from Moffitt; is a patent holder in Biodesix, and Moffitt; and received consulting fees from BMS, Merck, GSK, Genentech, Pfizer, Regeneron, Incyte, Biond, OncoC4, InstilBio, Moderna, and Evaxion.
Omid Hamid, MD, faculty for this educational event, has received research funding from Arcus, Aduro, Akeso, Amgen, Bioatla, BMS, Cytomx, Exelixis, Roche Genentech, GSK, Immunocore, Idera, Incyte, Iovance, Merck, Moderna, Merck Serono, Nextcure, Novartis, Pfizer, Regeneron, Seattle Genetics, Torque, Zelluna; received consulting fees from Alkermes, Amgen, Bactonix, Beigene, Bioatla, BMS, Eisai Biotech, Roche Genentech, Gerogiamune, GigaGen, Grit Bio, GSK, Idera, Immunocore, Incyte, Instilbio, IO Biotech, Iovance, Janssen, KSQ, Merck, Moderna, Novartis, Obsidian, Pfizer, Regeneron, Sanofi, Seattle Genetics, Tempus, Vial Health Tech, Zelluna; and has ownership interest in Bactonix.
Jason J. Luke, MD, FACP, faculty for this education event, has served on DSMB for Abbvie, Agenus, Immutep, and Evaxion; served on scientific advisory board for (no stock) 7 Hills, Affivant, BioCytics, Bright Peak, Exo, Fstar, Inzen, RefleXion, Xilio, (stock) Actym, Alphamab Oncology, Arch Oncology, Duke Street Bio, Kanaph, Mavu, NeoTx, Onc.AI, OncoNano, physIQ, Pyxis, Saros, STipe, and Tempest; received consulting fees from Abbvie, Agenus, Alnylam, AstraZeneca, Atomwise, Bayer, Bristol-Myers Squibb, Castle, Checkmate, Codiak, Crown, Cugene, Curadev, Day One, Eisai, EMD Serono, Endeavor, Flame, G1 Therapeutics, Genentech, Gilead, Glenmark, HotSpot, Kadmon, Ko Bio Labs, Krystal, KSQ, Janssen, Ikena, Inzen, Immatics, Immunocore, Incyte, Instil, IO Biotech, LegoChem, Macrogenics, Merck, Mersana, Nektar, Novartis, Partner, Pfizer, Pioneering Medicines, PsiOxus, Regeneron, Replimmune, Ribon, Roivant, Servier, STINGthera, Sumoitomo, Synlogic, Synthekine, and Teva; received research support (to the institution for clinical trials) from AbbVie, Astellas, Astrazeneca, Bristol-Myers Squibb, Corvus, Day One, EMD Serono, Fstar, Genmab, Hot Spot, Ikena, Immatics, Incyte, Kadmon, KAHR, Macrogenics, Merck, Moderna, Nektar, Next Cure, Novartis, Numab, Palleon, Pfizer, Replimmune, Rubius, Servier, Scholar Rock, Synlogic, Takeda, Trishula, Tizona, and Xencor; holds patent US-11638728.
Sapna Patel, MD, faculty for this educational event, has received research funding from Bristol-Myers Squibb, Foghorn Therapeutics, Ideaya, InxMed, Lyvgen, Novartis, Provectus, Seagen, Syntrix Bio, and TriSalus Life Sciences; and received consulting fees from Bristol-Myers Squibb, Cardinal Health, Castle Biosciences, Delcath, Immatics, Immunocore, Novartis, Pfizer, Replimune, and TriSalus Life Sciences.
Ryan Sullivan, MD, faculty for this educational event, has received research funding from Merck, and Novartis; and received consulting fees from BMS, Merck, Novartis, Pfizer, Marengo, and Replimune.